Press Releases Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 13/03/2026 pm IST			5-day change	1st Jan Change
2,818.50 ^JPY	-2.81%		-1.69%	-15.82%

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT

Press Releases

11/03	FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone \| AstraZeneca and Daiichi Sankyo	AQ
10/03	Daiichi Sankyo : Patent Dispute Between Daiichi Sankyo and Seagen has Concluded	PU
09/03	ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer	BU
27/02	Daiichi Sankyo : ENHERTU® Supplemental New Drug Application Submitted in Japan as Adjuvant Therapy for Patients with HER2 Positive Early Breast Cancer	PU
24/02	Daiichi Sankyo : Announces Global Management Structure and Corporate Officers	PU
20/02	Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D	BU
19/02	ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer	BU
12/02	Daiichi Sankyo : DATROWAY® Supplemental New Drug Application Submitted in Japan for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy	PU
09/02	Daiichi Sankyo : Support for Victims of Floods in Southeast and South Asia	PU
04/02	DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo	BU
03/02	DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy	BU
30/01	Daiichi Sankyo : Notice on the Determined Basic Policy for Absorption-type Merger of Daiichi Sankyo with Its Wholly Owned Subsidiary, Daiichi Sankyo Business Associe (Simplified Merger/Short Form Merger)	PU
30/01	Daiichi Sankyo : FY2025 Q3 Financial ResultsPDF	PU
30/01	Daiichi Sankyo : FY2025 Q3 Reference DataPDF	PU
30/01	Daiichi Sankyo : FY2025 Q3 Presentation MaterialPDF	PU
22/01	Daiichi Sankyo : ENHERTU® Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer	PU
22/01	Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe	BU
21/01	Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology	AQ
20/01	Daiichi Sankyo - ENHERTU plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	AQ
19/01	Daiichi Sankyo Receives Prime Minister's Award for Japan Medical Research and Development Grand Prize	AQ
19/01	ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	BU
14/01	Daiichi Sankyo - TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	AQ
13/01	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	BU
09/01	Daiichi Sankyo : Achieves Net Zero Target Certification from Science Based Targets initiative	PU
07/01	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe	BU